[{"id":"9b0e7bf4-bb20-480b-bb6a-5b8c166fdc23","acronym":"STARLYTE","url":"https://clinicaltrials.gov/study/NCT01472887","created_at":"2021-01-18T06:08:34.898Z","updated_at":"2024-07-02T16:37:14.503Z","phase":"Phase 2","brief_title":"SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients","source_id_and_acronym":"NCT01472887 - STARLYTE","lead_sponsor":"Sanofi","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e coltuximab ravtansine (SAR3419)"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 01/01/2012","start_date":" 01/01/2012","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 09/01/2016","study_completion_date":" 09/01/2016","last_update_posted":"2018-01-25"}]